December 2 Bristol-Myers Squibb Enters Clinical Collaboration Agreement with Tibotec Pharmaceuticals for Phase II Combination Study in Patients Chronically Infected with Hepatitis C December 1 NPS Pharmaceuticals Completes Submission of New Drug Application for GATTEX(R) (teduglutide) in Adult Short Bowel Syndrome (SBS) Aegerion Pharmaceuticals to Participate in the 2011 Deutsche Bank BioFEST Conference Amicus Therapeutics… Read the full article
Biolines December 2011
Industry News and Notes – December 2011
Washington Report BIO Applauds Congress for Reauthorizing SBIR/STTR Programs WASHINGTON, DC — The Biotechnology Industry Organization (BIO) on December 16 praised the House and Senate for passage of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) reauthorization as part of the National Defense Authorization Act (HR 1540). The passage of this Act… Read the full article
Membership Update – December 2011
BioNJ welcomes The Medicines Company as a new Platinum Member for 2011. The Medicines Company The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. We have three marketed products: Angiomax® (bivalirudin), Cleviprex® (clevidipine) injectable emulsion,… Read the full article
BioNJ Headlines – December 2011
BioNJ Presents Fifth Annual Dr. Sol J. Barer Award for Vision, Innovation, and Leadership to Paul G. Thomas of Roka Bioscience Paul G. Thomas, Founder and CEO of Roka Bioscience TRENTON, NJ – BioNJ, New Jersey’s trade association for the biotechnology community, announced on December 15 that the fifth annual Dr. Sol J. Barer Award… Read the full article
A Year of Friends, Hope, and Inspiration
With the end of the year approaching, I think everyone will agree that 2011 is ending on a high note for the New Jersey biotechnology community. There is so much for which we should be thankful and so many people to thank. In this final column for 2011, I would like to highlight: Our great… Read the full article